Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Novel treatments show promising results in patients with different hematologic disorders

In recent years, a number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. Studies presented today at the 56th Annual Meeting of the American Society of Hematology highlight the enormous potential these novel treatments have for patients with a variety of hematologic disorders.

7 Dec 2014

Adding maintenance therapy after transplant can improve outcomes in Hodgkin lymphoma patients

In a late-stage clinical trial, Hodgkin lymphoma (HL) patients who received brentuximab vedotin (BV) post-transplant lived longer without disease progression than patients who received only supportive care. This is the first time a study has demonstrated that adding a maintenance therapy after transplant can improve outcomes.

7 Dec 2014

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Novel treatments that harness the body's own immune cells to attack cancer cells demonstrate safe and durable responses in patients with relapsed and treatment-resistant blood cancers, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

FDA grants Orphan Drug Designation to Juno's JCAR015 leukemia T cell product candidate

Juno Therapeutics, Inc. announced today that the FDA has granted Orphan Drug Designation to its JCAR015 chimeric antigen receptor product candidate. The designation was granted for treatment of acute lymphoblastic leukemia. JCAR015 Phase I trials are currently underway at Juno's collaboration partner, Memorial Sloane Kettering Cancer Center.

18 Nov 2014

Newly-identified cancer cell fingerprints in the blood could help diagnose childhood cancer

Newly-identified cancer cell fingerprints in the blood could one day help doctors diagnose a range of children's cancers faster and more accurately, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference next week.

3 Nov 2014

Stem cell technologies market expected to show annual increase of 16.2% over 2010-2020

Though therapies are in their nascent phase, sales of stem cell technologies are expected to show an annual increase of 16.2% over the 2010-2020 period, reaching an expected market value of nearly $1 billion, according to Kalorama Information's report, Stem Cell Therapeutics Markets.

31 Oct 2014

Medac Pharma launches Rasuvo (methotrexate) injection for patients with RA, pJIA and psoriasis

Medac Pharma, Inc., a privately held pharmaceutical company, has announced the launch of its lead product Rasuvo (methotrexate) injection for patients with rheumatoid arthritis (RA), poly-articular-course juvenile idiopathic arthritis (pJIA) and psoriasis in the U.S.

6 Oct 2014

Amgen seeks FDA approval for leukemia drug blinatumomab

Amgen today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration seeking approval for its investigational bispecific T cell engager (BiTE) antibody construct, blinatumomab.

22 Sep 2014

PET-CT more accurate than conventional CT in evaluating patients with follicular lymphoma

Positron emission tomography/computed tomography (PET-CT) is more accurate than conventional CT scanning in measuring response to treatment and predicting survival in patients with follicular lymphoma, and should be used routinely in clinical practice, according to new research published in The Lancet Haematology.

19 Sep 2014

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the acquisition of a novel orphan drug candidate, known as SGX301 (synthetic hypericin).

8 Sep 2014

Infinity and AbbVie enter into global collaboration to develop and commercialize duvelisib

Infinity Pharmaceuticals, Inc. and AbbVie Inc. today announced that they have entered into a global collaboration to develop and commercialize duvelisib (IPI-145), Infinity's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of patients with cancer.

3 Sep 2014

Dasatinib: Leukemia drug shows promise for treating skin, breast and other cancers

A leukemia drug called dasatinib shows promise for treating skin, breast and several other cancers, according to researchers at Loyola University Chicago Stritch School of Medicine.

20 Aug 2014

Blood cancer patients in the UK can now benefit from Roche's MabThera SC

Patients with one of the most common forms of blood cancer can now benefit from a new injection. MabThera subcutaneous (SC), which is given to patients just beneath the skin, can be administered in approximately five minutes, compared to the current two and a half hour intravenous (IV) infusion.

6 Aug 2014

FDA approves use of Imbruvica to treat patients with chronic lymphocytic leukemia

The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use.

29 Jul 2014

Zydelig gets FDA approval for treatment of patients with three types of blood cancers

The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers.

24 Jul 2014

Study reveals why survival for blood cancer patients still varies between regions within Europe

Failure to get the best treatment and variations in the quality of care are the most likely reasons why survival for blood cancer patients still varies widely between regions within Europe, according to the largest population-based study of survival in European adults to date, published in The Lancet Oncology.

15 Jul 2014

Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced that the U.S. Food and Drug Administration has approved Rasuvo, a subcutaneous injectable methotrexate (MTX) therapy delivered in an auto-injector for rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis (pJIA) and psoriasis.

14 Jul 2014

Penn’s immunotherapy receives FDA's Breakthrough Therapy designation for ALL treatment

A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration's Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia (ALL).

7 Jul 2014

Beleodaq gets FDA approval for treatment of patients with peripheral T-cell lymphoma

The U.S. Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action was taken under the agency's accelerated approval program.

3 Jul 2014

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology.

3 Jul 2014

Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Novel treatments show promising results in patients with different hematologic disorders

Adding maintenance therapy after transplant can improve outcomes in Hodgkin lymphoma patients

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

FDA grants Orphan Drug Designation to Juno's JCAR015 leukemia T cell product candidate

Newly-identified cancer cell fingerprints in the blood could help diagnose childhood cancer

Stem cell technologies market expected to show annual increase of 16.2% over 2010-2020

Medac Pharma launches Rasuvo (methotrexate) injection for patients with RA, pJIA and psoriasis

Amgen seeks FDA approval for leukemia drug blinatumomab

PET-CT more accurate than conventional CT in evaluating patients with follicular lymphoma

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Infinity and AbbVie enter into global collaboration to develop and commercialize duvelisib

Dasatinib: Leukemia drug shows promise for treating skin, breast and other cancers

Blood cancer patients in the UK can now benefit from Roche's MabThera SC

FDA approves use of Imbruvica to treat patients with chronic lymphocytic leukemia

Zydelig gets FDA approval for treatment of patients with three types of blood cancers

Study reveals why survival for blood cancer patients still varies between regions within Europe

Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Penn’s immunotherapy receives FDA's Breakthrough Therapy designation for ALL treatment

Beleodaq gets FDA approval for treatment of patients with peripheral T-cell lymphoma

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in